When was Juniper Pharma founded?

Juniper Pharma was founded in 1986.

Where is Juniper Pharma located?

Juniper Pharma is headquartered in Boston, United States.

How many employees does Juniper Pharma have?

As of Dec 31, 2017, Juniper Pharma has 13 employees, reflecting a 23% year-over-year decline in headcount.

How much is Juniper Pharma worth?

The last known valuation of Juniper Pharma was $***** as of Jul 01, 2018.

Where does Juniper Pharma rank among its competitors?

Juniper Pharma ranks 37th amongst 37 active competitors, of which 8 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Agile Therapeutics, which secured $275K in Feb, 2024.

Who are the top competitors of Juniper Pharma?

Juniper Pharma's top competitors include Agile Therapeutics, Prescient Therapeutics and Marius Pharmaceuticals. Among them, Agile Therapeutics secured the most recent funding round in February, 2024.

Juniper Pharma - 2026 Company Profile & Competitors

Company Details

Global leader enabling pharma, biotech, and consumer health product optimization. The company optimizes product development, launch, and full life-cycle supply. It offers integrated development solutions, bioavailability enhancement, and a suite of technologies for oral dose forms, biologics, and advanced therapeutics. Services include preclinical development, formulation, analytical solutions, manufacturing, packaging, and regulatory support. The company supports clinical supply forecasting, comparator sourcing, and distribution. It caters to consumer over-the-counter products, nutritional supplements, and beauty products. The company focuses on cell and gene therapy, inhalation, and injectable solutions. It provides solid-state characterization, method development, stability testing, and nitrosamine testing services. The company operates in Asia Pacific, Europe, Latin America, and North America. It emphasizes corporate responsibility, diversity, and inclusion.

Key Metrics

Founded Year

1986

Location

Boston, United States

Stage

Acqui-Hired

Last Known Valuation

$***** as on Jul 01, 2018

Ranked

37^th among 37 active competitors

Employee Count

13 as on Dec 31, 2017

Investment & Acquisitions

Molprofiles.co.uk

Similar Companies

Agile Therapeutics & 57 more

View Juniper Pharma's full profile

Juniper Pharma is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Catalent, Inc. CIN: 208737688 , United States, Active		$1 - $1M (As on May 31, 2019)	-	-
JUNIPER PHARMACEUTICALS, INC. CIN: 592758596 , United Kingdom, Active		-	13 (As on Dec 31, 2017)

Juniper Pharma is a funded company.

Juniper Pharma's employee count trend

Juniper Pharma has 13 employees as of Dec 17. The total employee count is 24.0% lower than what it was in Dec 16. Here is Juniper Pharma's employee count trend over the years:

Uncover Juniper Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Juniper Pharma include Agile Therapeutics, Prescient Therapeutics and Marius Pharmaceuticals. Here is the list of Top 10 competitors of Juniper Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Agile Therapeutics 1997, Princeton (United States), Acquired	Developer of therapeutics for women healthcare	$124M	Aisling Capital, Kaiser Permanente Ventures ... & 11 others	58/100
2nd	Prescient Therapeutics 1986, South Melbourne (Australia), Public	Targeted small molecule inhibitors of Ras and Akt pathway for the treatment of cancer	$3M	-	51/100
3rd	Marius Pharmaceuticals 2017, Raleigh (United States), Series B	Developer of an proprietary oral testosterone replacement therapy platform	$32.6M	Shah Capital	49/100
4th	Theramex 1970, London (United Kingdom), Acquired	Manufacturer of drugs for women's health	-	Thecarlylegroup.fr, Europa	49/100
5th	Peptonic Medical 2009, Vaxjo (Sweden), Public	Developer of therapeutics for the treatment of vaginal atrophy	$1.06M	Aggregate Media, Almi Invest & 1 others	46/100
6th	Auxilium Pharmaceuticals 1999, Philadelphia (United States), Acquired	Developer of therapeutics and drug-device combinations for urology and sexual health	$43M	Aisling Capital, Orbimed & 8 others	45/100
7th	Creative Medical Technologies 2011, Phoenix (United States), Public	Stem-cell based therapeutics for male and female reproductive health	-	-	43/100
8th	Bionovo 2002, Emeryville (United States), Public	Develops botanically-derived drugs for menopausal symptoms and cancer	$16.4M	Silicom Ventures, Centrecourt Asset Management ... & 1 others	42/100
9th	Microchips Biotech 1999, Lexington (United States), Acquired	Microchip-based implants for drug delivery	$90.7M	Medtronic, Polaris Partners & 8 others	42/100
10th	Asarina Pharma 2006, Umea (Sweden), Series A	Developer of drugs for the premenstrual dysphoric disorder (PMDD)	$28M	Idinvest Partners, Ergomed & 7 others	40/100
37th	Juniper Pharma 1986, Boston (United States), Acqui-Hired	Global leader enabling pharma, biotech, and consumer health product optimization	-	-	23/100